Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new GLP-1-class drug is showing benefits well beyond weight loss. The phase 3 TRIUMPH-1 trial found that retatrutide — a triple-receptor agonist — significantly reduced knee osteoarthritis pain and body weight in adults with obesity over 80 weeks. Patients on the highest dose lost an average of 25% of their body weight and reported up to 61.6% reduction in knee pain.
A new contender in obesity treatment is showing benefits well beyond the scale. The phase 3 TRIUMPH-1 trial, published in The New England Journal of Medicine, found that retatrutide (Eli Lilly) — a triple-receptor agonist targeting GIP, GLP-1, and glucagon receptors — significantly reduced both body weight and knee osteoarthritis (OA) pain in adults with obesity over 80 weeks. The randomized, double-blind, placebo-controlled study enrolled 2,339 adults across 121 sites in 11 countries.
Beyond joint pain and weight, retatrutide also improved obstructive sleep apnea severity and cardiometabolic markers including blood pressure, triglycerides, and inflammation levels — rounding out an impressive multi-system benefit profile.
By the Numbers:
Why it matters: For the millions of patients living with both obesity and knee osteoarthritis, retatrutide could offer a single treatment that addresses weight, joint pain, sleep apnea, and heart health — a meaningful step forward in managing these often intertwined conditions.
